RxDoctor Payments Data

Charles Givens, MD

Family Medicine · Reading, PANPI 1336140599

Payments from drug & device makers

$3,070in general payments, 2019–2025

Across 199 payments — averaging $15.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$626
  • Pfizer$418
  • Boehringer Ingelheim$353
  • AstraZeneca$239
  • Lilly USA, LLC$228
  • AbbVie$169
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,00898%
  • Education$622%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,070 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$186,826
Medicare patients
468
Services billed
1,834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban129$117,084
JanuviaSitagliptin Phosphate88$75,219
JardianceEmpagliflozin63$62,866
OzempicSemaglutide41$48,034
XareltoRivaroxaban43$38,297
FarxigaDapagliflozin Propanediol35$35,475
MounjaroTirzepatide24$32,121
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$16,576
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$14,165
Breo ElliptaFluticasone/Vilanterol17$13,546
TrulicityDulaglutide13$12,337
TradjentaLinagliptin12$11,625
ElmironPentosan Polysulfate Sodium12$7,982
Atorvastatin Calcium720$7,356
Tegretol XrCarbamazepine13$6,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$418$117,084129 claims
MerckJanuvia, Dulera$110$79,158101 claims
Boehringer IngelheimJardiance, Tradjenta, Pradaxa$353$76,90488 claims
Novo NordiskOzempic$626$48,03441 claims
Lilly USA, LLCMounjaro, Trulicity$228$44,45937 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$154$44,28760 claims
Johnson & JohnsonXarelto$14$38,29743 claims
AstraZenecaFarxiga$239$35,47535 claims
AbbVieLumigan, Synthroid$169$6,29081 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Reading

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →